B-PC 157 has positive effects on the digestive system and supports the healing of gastrointestinal diseases
Lixisenatide (ELIXA trial), liraglutide (LEADER trial), subcutaneous semaglutide (SUSTAIN-6 trial), exenatide (EXSCEL trial), and dulaglutide (REWIND trial) were GLP-1 RA drugs evaluated for kidney outcomes in this meta-analysis [data for kidney events were not available for albiglutide (Harmony Outcomes) or oral semaglutide (PIONEER 6), so this analysis excluded the outcomes of these trials] [55]
Both side effects on GLP-1 medications can become significant if fluid intake is inadequate
One potential explanation for this finding is the high levels of stress-induced alterations in gene expression (e.g., increased expression of mitochondrial transcripts) within this subcluster
C ch: Cc qu trnh xy dng t bo mi, sa cha cc m tn thng lun c s tham gia ca Glutathione, gip tng cng h thng min dch
The gastrointestinal effects , including diarrhea, nausea, and vomiting, can lead to dehydration , which intensifies dry mouth symptoms